NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).

A. Wainberg, Zev; Melisi, Davide; Macarulla, Teresa; Pazo-Cid, Roberto; R Chandana, Sreenivasa; de la Fouchardière, Christelle; Dean, Andrew; Kišš, Igor; Lee, Woo‐Jin; Oliver Goetze, Thorsten; Van Cutsem, Eric; Scott Paulson, Andrew; Bekaii‐Saab, Tanios; Pant, Shubham; Hubner, Richard; Xiao, Zhimin; Chen, Huanyu; Benzaghou, Fawzi; M. O’Reilly, Eileen

doi:10.1200/jco.2023.41.4_suppl.lba661

Public

NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).

Published in Journal of Clinical Oncology • Jan 24, 2023

Authors:

Zev A. Wainberg

Davide Melisi

Teresa Macarulla

Abstract

LBA661 Background: Liposomal irinotecan administered with 5-fluorouracil/leucovorin (5-FU/LV) is approved in the USA and Europe for mPDAC following progression with gemcitabine-based therapy. A phase 1/2 study (Wainberg et al. Eur J Cancer 2021;151:14–24; NCT02551991) demonstrated promising anti-tum...

View

Paywalled

Subject

Medicine

Gemcitabine

Oxaliplatin

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Subject

Generate AI Take for this paper

Discussions